USA - NASDAQ:NVAX - US6700024010 - Common Stock
We assign a fundamental rating of 4 out of 10 to NVAX. NVAX was compared to 534 industry peers in the Biotechnology industry. There are concerns on the financial health of NVAX while its profitability can be described as average. NVAX has a decent growth rate and is not valued too expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 31.64% | ||
| ROE | 1123.78% | ||
| ROIC | 30.55% |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 33.97% | ||
| PM (TTM) | 39.2% | ||
| GM | 88.3% |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 5.93 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -1.76 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.36 | ||
| Quick Ratio | 2.34 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 4.35 | ||
| Fwd PE | 55.16 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 1.57 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
8.52
+0.16 (+1.91%)
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 4.35 | ||
| Fwd PE | 55.16 | ||
| P/S | 1.28 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 36.78 | ||
| P/tB | N/A | ||
| EV/EBITDA | 1.57 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 31.64% | ||
| ROE | 1123.78% | ||
| ROCE | 38.67% | ||
| ROIC | 30.55% | ||
| ROICexc | 86.37% | ||
| ROICexgc | 130.29% | ||
| OM | 33.97% | ||
| PM (TTM) | 39.2% | ||
| GM | 88.3% | ||
| FCFM | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 5.93 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 0.55 | ||
| Cap/Depr | 11.6% | ||
| Cap/Sales | 0.44% | ||
| Interest Coverage | 18.14 | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.36 | ||
| Quick Ratio | 2.34 | ||
| Altman-Z | -1.76 |
ChartMill assigns a fundamental rating of 4 / 10 to NVAX.
ChartMill assigns a valuation rating of 6 / 10 to NOVAVAX INC (NVAX). This can be considered as Fairly Valued.
NOVAVAX INC (NVAX) has a profitability rating of 5 / 10.
The financial health rating of NOVAVAX INC (NVAX) is 3 / 10.